{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:59:44Z","timestamp":1790614784739,"version":"4.1.0"},"reference-count":98,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:p>Tryptase genotyping has an expanding role in the screening, diagnosis, and management of patients with systemic mastocytosis (SM). Reference ranges for basal serum tryptase (BST) based on increased <jats:italic>TPSAB1<\/jats:italic> gene copy number can guide whether a patient's BST value is normal according to their specific tryptase genotype. Patients with an elevated BST based upon their tryptase genotype should be offered a bone marrow biopsy with sample evaluation by a hematopathologist. Tryptase genotyping is required when assessing patients for the WHO minor criterion, BST\u2009&amp;gt;\u200920\u2005ng\/ml, especially in those with monoclonal mast cell activation syndrome, bone marrow mastocytosis (BMM), and indolent systemic mastocytosis (ISM) when the major criterion is not met. Additionally, in patients with non-advanced SM, tryptase genotyping helps determine whether a patient with hereditary-alpha tryptasemia (H\u03b1T) has BMM with a BST\u2009&amp;lt;\u2009125\u2005ng\/ml or fulfills the B-finding of BST\u2009&amp;gt;\u2009200\u2005ng\/ml through application of a correction factor. Understanding a patient's BST level based upon their tryptase genotype also is helpful in guiding when to pursue a repeat bone marrow biopsy in patients with SM treated with a tyrosine kinase inhibitor (TKI). However, TKIs have variable KIT D816V as well as wild type KIT inhibition. Given this variable KIT inhibition, ongoing and future clinical trials with selective TKIs should report whether patients with SM and H\u03b1T experience normalization or persistent elevation of BST values as this is essential in understanding the expected treatment response and when to assess for pathological remission in the bone marrow.<\/jats:p>","DOI":"10.3389\/falgy.2025.1599358","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T05:24:55Z","timestamp":1748323495000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Utility of tryptase genotyping in the screening, diagnosis, and management of systemic mastocytosis"],"prefix":"10.3389","volume":"6","author":[{"given":"Jeremy C.","family":"McMurray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon J.","family":"Schornack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy I.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan A.","family":"Boggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"11939","DOI":"10.1016\/S0021-9258(19)68496-6","article-title":"Tryptase from human pulmonary mast cells. Purification and characterization","volume":"256","author":"Schwartz","year":"1981","journal-title":". J Biol Chem"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.4049\/jimmunol.126.4.1290","article-title":"Acid hydrolases and tryptase from secretory granules of dispersed human lung mast cells","volume":"126","author":"Schwartz","year":"1981","journal-title":"J Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/185846a0","article-title":"Histochemical demonstration of a species-specific trypsin-like enzyme in mast cells","volume":"185","author":"Glenner","year":"1960","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1073\/pnas.83.12.4464","article-title":"Two types of human mast cells that have distinct neutral protease compositions","volume":"83","author":"Irani","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"B5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3748\/wjg.v10.i3.323","article-title":"Modulation of tryptase secretion from human colon mast cells by histamine","volume":"10","author":"He","year":"2004","journal-title":"World J Gastroenterol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0022-3565(24)37586-X","article-title":"A role for tryptase in the activation of human mast cells: modulation of histamine release by tryptase and inhibitors of tryptase","volume":"286","author":"He","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jmb.2004.10.029","article-title":"Structural requirements and mechanism for heparin-dependent activation and tetramerization of human betaI- and betaII-tryptase","volume":"345","author":"Hallgren","year":"2005","journal-title":"J Mol Biol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"13068","DOI":"10.1021\/bi000973b","article-title":"Mechanism for activation of mouse mast cell tryptase: dependence on heparin and acidic pH for formation of active tetramers of mouse mast cell protease 6","volume":"39","author":"Hallgren","year":"2000","journal-title":"Biochemistry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.4049\/jimmunol.173.3.1868","article-title":"Histidines are critical for heparin-dependent activation of mast cell tryptase","volume":"173","author":"Hallgren","year":"2004","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1172\/JCI118523","article-title":"A novel heparin-dependent processing pathway for human tryptase. Autocatalysis followed by activation with dipeptidyl peptidase I","volume":"97","author":"Sakai","year":"1996","journal-title":"J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1016\/j.jaip.2021.12.031","article-title":"Elevated basal serum tryptase: disease distribution and variability in a regional health system","volume":"10","author":"Waters","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1172\/JCI118337","article-title":"The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis","volume":"96","author":"Schwartz","year":"1995","journal-title":"J Clin Invest"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.6004\/jnccn.2024.0030","article-title":"NCCN Guidelines\u00ae insights: systemic mastocytosis, version 3.2024","volume":"22","author":"Gotlib","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat Genet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1182\/bloodadvances.2022007936","article-title":"Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms","volume":"7","author":"Chovanec","year":"2023","journal-title":"Blood Adv"},{"key":"B18","doi-asserted-by":"publisher","first-page":"6072","DOI":"10.4049\/jimmunol.179.9.6072","article-title":"Mast cell alpha and beta tryptases changed rapidly during primate speciation and evolved from gamma-like transmembrane peptidases in ancestral vertebrates","volume":"179","author":"Trivedi","year":"2007","journal-title":"J Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1073\/pnas.87.10.3811","article-title":"Human mast cell tryptase: multiple cDNAs and genes reveal a multigene serine protease family","volume":"87","author":"Vanderslice","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1074\/jbc.274.6.3355","article-title":"Characterization of genes encoding known and novel human mast cell tryptases on chromosome 16p13.3","volume":"274","author":"Pallaoro","year":"1999","journal-title":"J Biol Chem"},{"key":"B21","doi-asserted-by":"publisher","first-page":"6566","DOI":"10.4049\/jimmunol.164.12.6566","article-title":"Characterization of human gamma-tryptases, novel members of the chromosome 16p mast cell tryptase and prostasin gene families","volume":"164","author":"Caughey","year":"2000","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.jaci.2008.01.019","article-title":"Chimerism, point mutation, and truncation dramatically transformed mast cell delta-tryptases during primate evolution","volume":"121","author":"Trivedi","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"49169","DOI":"10.1074\/jbc.M108677200","article-title":"Human tryptase epsilon (PRSS22), a new member of the chromosome 16p13.3 family of human serine proteases expressed in airway epithelial cells","volume":"276","author":"Wong","year":"2001","journal-title":"J Biol Chem"},{"key":"B24","doi-asserted-by":"publisher","first-page":"30784","DOI":"10.1074\/jbc.274.43.30784","article-title":"Identification of a new member of the tryptase family of mouse and human mast cell proteases which possesses a novel COOH-terminal hydrophobic extension","volume":"274","author":"Wong","year":"1999","journal-title":"J Biol Chem"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5667","DOI":"10.4049\/jimmunol.170.11.5667","article-title":"Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, mono-Mac-6 cells, and human skin-derived mast cells","volume":"170","author":"Schwartz","year":"2003","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.jaci.2009.07.026","article-title":"Human subjects are protected from mast cell tryptase deficiency despite frequent inheritance of loss-of-function mutations","volume":"124","author":"Trivedi","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/s0022-2836(02)00625-3","article-title":"The crystal structure of human alpha1-tryptase reveals a blocked substrate-binding region","volume":"321","author":"Marquardt","year":"2002","journal-title":"J Mol Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1021\/bi015662v","article-title":"Diverse stability and catalytic properties of human tryptase alpha and beta isoforms are mediated by residue differences at the S1 pocket","volume":"41","author":"Selwood","year":"2002","journal-title":"Biochemistry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"19670","DOI":"10.1074\/jbc.274.28.19670","article-title":"Human tryptases alpha and beta\/II are functionally distinct due, in part, to a single amino acid difference in one of the surface loops that forms the substrate-binding cleft","volume":"274","author":"Huang","year":"1999","journal-title":"J Biol Chem"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1084\/jem.20190701","article-title":"Impact of naturally forming human \u03b1\/\u03b2-tryptase heterotetramers in the pathogenesis of hereditary \u03b1-tryptasemia","volume":"216","author":"Le","year":"2019","journal-title":"J Exp Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1016\/j.jaip.2020.05.057","article-title":"Hereditary alpha-tryptasemia: UK prevalence and variability in disease expression","volume":"8","author":"Robey","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B32","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.anai.2021.08.009","article-title":"Clinical relevance of inherited genetic differences in human tryptases: hereditary alpha-tryptasemia and beyond","volume":"127","author":"Glover","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1038\/s41598-024-52983-8","article-title":"Clinically accessible amplitude-based multiplex ddPCR assay for tryptase genotyping","volume":"14","author":"Svetina","year":"2024","journal-title":"Sci Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/clinchem\/hvad206","article-title":"Hereditary alpha tryptasemia: validation of a single-well Multiplex digital droplet PCR assay in a cohort of symptomatic patients","volume":"70","author":"Alheraky","year":"2024","journal-title":"Clin Chem"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e0291947","DOI":"10.1371\/journal.pone.0291947","article-title":"A targeted amplicon next-generation sequencing assay for tryptase genotyping to support personalized therapy in mast cell-related disorders","volume":"19","author":"Li","year":"2024","journal-title":"PLoS One"},{"key":"B36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0022-1759(86)90277-2","article-title":"Immunoassay of tryptase from human mast cells","volume":"86","author":"Wenzel","year":"1986","journal-title":"J Immunol Methods"},{"key":"B37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0022-1759(91)90062-k","article-title":"A new radioimmunoassay for human mast cell tryptase using monoclonal antibodies","volume":"138","author":"Enander","year":"1991","journal-title":"J Immunol Methods"},{"key":"B38","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/BF01533368","article-title":"Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis","volume":"14","author":"Schwartz","year":"1994","journal-title":"J Clin Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: consensus report of the European competence network on mastocytosis; the American academy of allergy, asthma & immunology; and the European academy of allergology and clinical immunology","volume":"137","author":"Hartmann","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT Mutation analysis in mast cell neoplasms: recommendations of the European competence network on mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13246380","article-title":"A multidisciplinary diagnostic approach reveals a higher prevalence of indolent systemic mastocytosis: 15-Years\u2019 experience of the GISM network","volume":"13","author":"Zanotti","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/bjh.12916","article-title":"Epidemiology of systemic mastocytosis in Denmark","volume":"166","author":"Cohen","year":"2014","journal-title":"Br J Haematol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.jaci.2021.04.013","article-title":"Prevalence of mastocytosis and hymenoptera venom allergy in the United States","volume":"148","author":"Schuler","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2340\/1651-226X.2024.31406","article-title":"Epidemiology of mastocytosis: a population-based study (Sweden)","volume":"63","author":"Bergstr\u00f6m","year":"2024","journal-title":"Acta Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejim.2016.01.005","article-title":"Systemic mastocytosis: a cohort study on clinical characteristics of 136 patients in a large tertiary centre","volume":"30","author":"Hermans","year":"2016","journal-title":"Eur J Intern Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers14163942","article-title":"Clinical outcomes of adults with systemic mastocytosis: a 15-year multidisciplinary experience","volume":"14","author":"Ungerstedt","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B47","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12885-022-10498-3","article-title":"Comprehensive mastocytosis data analysis from a single center","volume":"23","author":"Tiryaki","year":"2023","journal-title":"BMC Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e638","DOI":"10.1016\/S2352-3026(19)30166-8","article-title":"International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study","volume":"6","author":"Sperr","year":"2019","journal-title":"Lancet Haematol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/modpathol.2011.84","article-title":"Evaluation of the WHO criteria for the classification of patients with mastocytosis","volume":"24","author":"S\u00e1nchez-Mu\u00f1oz","year":"2011","journal-title":"Mod Pathol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1111\/all.14248","article-title":"Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification","volume":"75","author":"Trizuljak","year":"2020","journal-title":"Allergy"},{"key":"B51","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/ajh.24382","article-title":"Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients","volume":"91","author":"Pieri","year":"2016","journal-title":"Am J Hematol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e85362","DOI":"10.1371\/journal.pone.0085362","article-title":"ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases","volume":"9","author":"Damaj","year":"2014","journal-title":"PLoS One"},{"key":"B53","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/bloodadvances.2022008292","article-title":"Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM registry","volume":"7","author":"Kennedy","year":"2022","journal-title":"Blood Adv"},{"key":"B55","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.iac.2018.04.006","article-title":"Patient perceptions in mast cell disorders","volume":"38","author":"Jennings","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"B56","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaip.2013.09.004","article-title":"The mastocytosis society survey on mast cell disorders: patient experiences and perceptions","volume":"2","author":"Jennings","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.jaip.2018.07.032","article-title":"The mastocytosis society survey on mast cell disorders: part 2-patient clinical experiences and beyond","volume":"7","author":"Russell","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1111\/all.12920","article-title":"Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis","volume":"71","author":"van Anrooij","year":"2016","journal-title":"Allergy"},{"key":"B59","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1002\/cncr.34421","article-title":"Perceptions of patient disease burden and management approaches in systemic mastocytosis: results of the TouchStone healthcare provider survey","volume":"128","author":"Mesa","year":"2022","journal-title":"Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"key":"B61","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/cea.12225","article-title":"High prevalence of anaphylaxis in patients with systemic mastocytosis - a single-centre experience","volume":"44","author":"G\u00fclen","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1111\/j.1365-2222.2007.02804.x","article-title":"Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA)","volume":"37","author":"Gonz\u00e1lez de Olano","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"B63","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/j.1398-9995.2011.02780.x","article-title":"High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis","volume":"67","author":"van der Veer","year":"2012","journal-title":"Allergy"},{"key":"B64","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.bone.2011.07.004","article-title":"Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis","volume":"49","author":"Rossini","year":"2011","journal-title":"Bone"},{"key":"B65","doi-asserted-by":"publisher","first-page":"4459","DOI":"10.1016\/j.jaip.2021.08.001","article-title":"Assessment of osteoporosis and fracture risk in mastocytosis within a north American cohort","volume":"9","author":"Makovoz","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B66","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.bone.2017.09.005","article-title":"Prevalence and risk factors for fragility fracture in systemic mastocytosis","volume":"105","author":"Degbo\u00e9","year":"2017","journal-title":"Bone"},{"key":"B67","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1182\/blood.2023023347","article-title":"Standardized indolent systemic mastocytosis evaluations across a health care system: implications for screening accuracy","volume":"144","author":"McMurray","year":"2024","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1182\/bloodadvances.2023009826","article-title":"Challenges in applying diagnostic criteria for systemic mastocytosis","volume":"7","author":"Boggs","year":"2023","journal-title":"Blood Adv"},{"key":"B69","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jaci.2021.02.043","article-title":"Routine KIT p.D816V screening identifies clonal mast cell disease in patients with hymenoptera allergy regularly missed using baseline tryptase levels alone","volume":"148","author":"\u0160elb","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/bjd.20098","article-title":"Cutaneous mastocytosis in adults with a serum tryptase level < 20ng mL-1\u202f: why we should investigate further","volume":"185","author":"Jendoubi","year":"2021","journal-title":"Br J Dermatol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jaci.2010.02.019","article-title":"Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms","volume":"125","author":"Alvarez-Twose","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000329856","article-title":"Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms","volume":"157","author":"Alvarez-Twose","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/modpathol.2013.117","article-title":"Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis","volume":"27","author":"Berezowska","year":"2014","journal-title":"Mod Pathol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"117141","DOI":"10.1016\/j.bone.2024.117141","article-title":"Underlying systemic mastocytosis in patients with unexplained osteoporosis: score proposal","volume":"186","author":"Tanasi","year":"2024","journal-title":"Bone"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1056\/NEJM198312293092603","article-title":"Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites","volume":"309","author":"Keyzer","year":"1983","journal-title":"N Engl J Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/1523-1747.ep12606209","article-title":"Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2","volume":"104","author":"Morrow","year":"1995","journal-title":"J Invest Dermatol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1111\/all.12668","article-title":"Urinary 11\u03b2-PGF2\u03b1 and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders","volume":"70","author":"Divekar","year":"2015","journal-title":"Allergy"},{"key":"B78","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.clinbiochem.2016.02.007","article-title":"Analytical and clinical validation of an LC-MS\/MS method for urine leukotriene E4: a marker of systemic mastocytosis","volume":"49","author":"Lueke","year":"2016","journal-title":"Clin Biochem"},{"key":"B79","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/s0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1016\/j.jaip.2024.08.044","article-title":"Harmonization of diagnostic criteria in mastocytosis for use in clinical practice: WHO vs ICC vs AIM\/ECNM","volume":"12","author":"Valent","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1097\/01.pas.0000138181.89743.7b","article-title":"CD25 Indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens","volume":"28","author":"Sotlar","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ajcp\/aqaf008","article-title":"High-sensitivity KIT D816V variation analysis by droplet digital polymerase chain reaction: the reference laboratory perspective","author":"Shean","year":"2025","journal-title":"Am J Clin Pathol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/leu.2017.234","article-title":"Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial","volume":"32","author":"DeAngelo","year":"2018","journal-title":"Leukemia"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"68950","DOI":"10.18632\/oncotarget.10711","article-title":"Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature","volume":"8","author":"Alvarez-Twose","year":"2017","journal-title":"Oncotarget"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/EVIDoa2200339","article-title":"Avapritinib versus placebo in indolent systemic mastocytosis","volume":"2","author":"Gotlib","year":"2023","journal-title":"NEJM evid"},{"key":"B89","first-page":"1","article-title":"Analysis of hereditary alpha tryptasemia and AssociationWith baseline characteristics in patients with IndolentSystemic mastocytosis enrolled on the PIONEER study","volume-title":"American Initiative in Mast Cell Diseases (AIM) Conference;","author":"Castells","year":"2024"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/1535-7163.TARG-21-P257","article-title":"Preclinical data identifies bezuclastinib as a differentiated KIT inhibitor with unique selectivity to KIT D816V and minimal evidence of brain penetration","volume":"20","author":"Guarnieri","year":"2021","journal-title":"Mol Cancer Ther."},{"key":"B91","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1182\/blood-2023-188904","article-title":"Elenestinib, an investigational, next generation KIT D816V inhibitor, reduces mast cell burden, improves symptoms, and has a favorable safety profile in patients with indolent systemic mastocytosis: analysis of the harbor trial","volume":"142","author":"Tashi","year":"2023","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1182\/blood-2004-12-4617","article-title":"Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412","volume":"106","author":"Growney","year":"2005","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","first-page":"e7258","DOI":"10.1371\/journal.pone.0007258","article-title":"Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT","volume":"4","author":"Dubreuil","year":"2009","journal-title":"PLoS One"},{"key":"B96","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","article-title":"PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects","volume":"107","author":"Gleixner","year":"2006","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.coi.2021.04.001","article-title":"Mast cell tryptases in allergic inflammation and immediate hypersensitivity","volume":"72","author":"Lyons","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1016\/j.intimp.2007.07.007","article-title":"Active monomers of human beta-tryptase have expanded substrate specificities","volume":"7","author":"Fukuoka","year":"2007","journal-title":"Int Immunopharmacol"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1599358\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T05:24:56Z","timestamp":1748323496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1599358\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":98,"alternative-id":["10.3389\/falgy.2025.1599358"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2025.1599358","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"article-number":"1599358"}}